Remediation of Age-related Cognitive Decline: Vortioxetine and Cognitive Training (BBS)
Sponsor: Queen's University
Listed as NCT03272711, this PHASE4 trial focuses on Age-related Cognitive Decline and remains completed. Sponsored by Queen's University, it has been updated 14 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Jun 2025 — Sep 2025 [monthly]
Completed PHASE4
-
Apr 2025 — Jun 2025 [monthly]
Completed PHASE4
-
Sep 2024 — Apr 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
▶ Show 9 earlier versions
-
Mar 2022 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2021 — Mar 2022 [monthly]
Completed PHASE4
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE4
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE4
-
Jun 2019 — Feb 2020 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Feb 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE4
-
Nov 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE4
-
Oct 2017 — Jun 2018 [monthly]
Recruiting PHASE4
First recorded
Aug 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Queen's University
- Takeda
- Washington University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .